SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel,...
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
Seeking Alpha / 3 hours ago 2 Views
Comments